Summary & Overview
HCPCS G0434: Non-Chromatographic Multiclass Drug Screen
HCPCS Level II code G0434 covers non-chromatographic drug screening for any number of drug classes performed per patient encounter using CLIA-waived or moderate complexity methods. This code is commonly used in outpatient and ambulatory settings for rapid toxicology screening in clinical, occupational, and substance-use contexts. Nationally, standardized reporting of such screens impacts clinical workflows, lab billing practices, and payer coverage determinations for point-of-care testing.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical scope and typical use cases, payer coverage considerations, and benchmarking elements relevant to billing and reimbursement workflows. The publication also outlines coding relationships and practical billing details such as service line placement and common modifiers where available.
This summary provides a national perspective for administrators, billing staff, and clinicians seeking clarity on when to report HCPCS Level II code G0434, what settings it applies to, and which major payers are relevant for coverage and claims processing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G0434 describes a drug screen, other than chromatographic; any number of drug classes, by CLIA waived test or moderate complexity test, per patient encounter. This service represents point-of-care or clinic-based toxicology testing that detects multiple drug classes using non-chromatographic methods.
Service type: Drug screening laboratory test
Typical site of service: Outpatient clinics, physician offices, urgent care centers, and other ambulatory settings where CLIA-waived or moderate complexity testing is performed per patient encounter.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient primary care clinic or urgent care with concerns for possible substance use, medication adherence, or new behavioral symptoms. The clinician performs a point-of-care or clinic-laboratory drug screening using a CLIA-waived immunoassay or a moderate-complexity laboratory test to detect one or more drug classes. Typical indications include monitoring adherence to prescribed controlled substances (e.g., opioids, benzodiazepines), evaluating suspected illicit drug use, pre-procedural screening, or as part of a medication-assisted treatment program for opioid use disorder. The workflow generally includes patient identification and consent, specimen collection (urine, oral fluid, or other acceptable specimen), running the waived or moderate-complexity assay in the clinic or sending it to the in-house moderate-complexity lab, documenting results in the medical record, and incorporating findings into the clinical plan. Billing uses HCPCS Level II code G0434 per patient encounter for any number of drug classes when performed by CLIA-waived or moderate complexity testing in the ambulatory setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation or physician component of the test separate from the technical component. |